Last reviewed · How we verify

Chronic Myeloid Leukemia (CML) — Treatment Landscape & Competitive Intelligence

Chronic Myeloid Leukemia (CML) (Haematology / Oncology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Haematology / Oncology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Myeloid Leukemia (CML), deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Synribo OMACETAXINE MEPESUCCINATE Teva Pharms Intl omacetaxine mepesuccinate 2012-01-01
Cytoxan (Lyophilized) cyclophosphamide Baxter Alkylating agent Tumor cell DNA 1959-01-01
Valchlor MECHLORETHAMINE Recordati Alkylating Drug [EPC] 1949-01-01
Cyclophosphamid Cyclophosphamid Zhejiang University Cytochrome P450 3A4
Siklos Siklos Theravia Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Xromi Xromi Nova Laboratories Limited Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Hydroxycarbamide Hydroxycarbamide University of Birmingham Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Homoharringtonine Homoharringtonine ChemGenex Pharmaceuticals
Hydroxycarbamid Hydroxycarbamid Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Omacetaxine Omacetaxine University of Illinois at Chicago

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Chronic Myeloid Leukemia (CML)
  2. Baxter · 2 drugs in Chronic Myeloid Leukemia (CML)
  3. Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · 1 drug in Chronic Myeloid Leukemia (CML)
  4. ChemGenex Pharmaceuticals · 1 drug in Chronic Myeloid Leukemia (CML)
  5. Nova Laboratories Limited · 1 drug in Chronic Myeloid Leukemia (CML)
  6. Recordati · 1 drug in Chronic Myeloid Leukemia (CML)
  7. Teva Pharms Intl · 1 drug in Chronic Myeloid Leukemia (CML)
  8. The Lymphoma Academic Research Organisation · 1 drug in Chronic Myeloid Leukemia (CML)
  9. Theravia · 1 drug in Chronic Myeloid Leukemia (CML)
  10. University of Birmingham · 1 drug in Chronic Myeloid Leukemia (CML)
  11. University of Illinois at Chicago · 1 drug in Chronic Myeloid Leukemia (CML)
  12. Zhejiang University · 1 drug in Chronic Myeloid Leukemia (CML)

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Myeloid Leukemia (CML):

Cite this brief

Drug Landscape (2026). Chronic Myeloid Leukemia (CML) — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-myeloid-leukemia. Accessed 2026-05-16.

Related